Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Instituto Sanitas and Chemopharma are Chilean pharmaceutical laboratories with more than a century of combined experience in the development, manufacturing and commercialization of medicines for the local healthcare market. Founded in the early 20th century, the companies have built a diversified portfolio of over 150 pharmaceutical products across multiple therapeutic areas, including cardiology, neuropsychiatry, analgesics and other treatments. They serve a broad network of customers through retail pharmacies, hospitals, clinics and public health institutions across Chile, positioning themselves as long-standing suppliers within the national pharmaceutical industry.
Laboratorios Saval is a Chilean pharmaceutical company with more than 85 years of experience in the development, manufacturing and commercialization of medicines and healthcare products. Founded in the late 1930s and headquartered in Santiago, the company has established itself as a leading player in the Chilean pharmaceutical market through a diversified product portfolio, modern manufacturing facilities and long-standing relationships with healthcare professionals and institutions. The company has also developed a significant regional footprint, with operations and commercial presence across more than 14 countries in Latin America, supported by subsidiaries, distributors, and production capabilities in the region.
The sellers are part of a Chilean conglomerate with a significant presence across multiple sectors, including agriculture, pharmaceuticals and real estate.
Oaklins’ team in Chile acted as the sole financial advisor in the transaction.
Sprechen Sie mit dem Deal Team
Transaktionen
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Mehr erfahrenDie Lindenhofgruppe veräussert ihre Mehrheitsbeteiligung an der LabPoint an Affidea Switzerland
Die LabPoint Medizinische Laboratorien AG wurde von Affidea Switzerland AG übernommen. Mit Affidea hat die Lindenhofgruppe AG einen starken strategischen Partner für die Weiterentwicklung der LabPoint gewonnen. Die Lindenhofgruppe bleibt bedeutende Aktionärin und Grosskundin des Unternehmens. Damit schafft sie die Grundlage für eine nachhaltige Weiterentwicklung von LabPoint unter einer neuen Ankeraktionärin. LabPoint soll ihre Position in der Labordiagnostik weiter stärken und gezielt ausbauen.
Mehr erfahrenEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Mehr erfahren